Stock Research for AGEN

AGEN

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AGEN Stock Chart & Research Data

The AGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AGEN Due diligence Resources & Stock Charts

The AGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AGEN Detailed Price Forecast - CNN Money CNN View AGEN Detailed Summary - Google Finance
Yahoo View AGEN Detailed Summary - Yahoo! Finance Zacks View AGEN Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View AGEN Trends & Analysis - Trade-Ideas Barrons View AGEN Major Holders - Barrons
NASDAQ View AGEN Call Transcripts - NASDAQ Seeking View AGEN Breaking News & Analysis - Seeking Alpha
Spotlight View AGEN Annual Report - CompanySpotlight.com OTC Report View AGEN OTC Short Report - OTCShortReport.com
TradeKing View AGEN Fundamentals - TradeKing Charts View AGEN SEC Filings - Bar Chart
WSJ View Historical Prices for AGEN - The WSJ Morningstar View Performance/Total Return for AGEN - Morningstar
MarketWatch View the Analyst Estimates for AGEN - MarketWatch CNBC View the Earnings History for AGEN - CNBC
StockMarketWatch View the AGEN Earnings - StockMarketWatch MacroAxis View AGEN Buy or Sell Recommendations - MacroAxis
Bullish View the AGEN Bullish Patterns - American Bulls Short Pains View AGEN Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View AGEN Stock Mentions - StockTwits PennyStocks View AGEN Stock Mentions - PennyStockTweets
Twitter View AGEN Stock Mentions - Twitter Invest Hub View AGEN Investment Forum News - Investor Hub
Yahoo View AGEN Stock Mentions - Yahoo! Message Board Seeking Alpha View AGEN Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for AGEN - SECform4.com Insider Cow View Insider Transactions for AGEN - Insider Cow
CNBC View AGEN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AGEN - OTC Markets
Yahoo View Insider Transactions for AGEN - Yahoo! Finance NASDAQ View Institutional Holdings for AGEN - NASDAQ


Stock Charts

FinViz View AGEN Stock Insight & Charts - FinViz.com StockCharts View AGEN Investment Charts - StockCharts.com
BarChart View AGEN Stock Overview & Charts - BarChart Trading View View AGEN User Generated Charts - Trading View


Latest Financial News for AGEN

Agenus Appoints Regulatory and Clinical Heads
Posted on Monday July 16, 2018

LEXINGTON, Mass., July 16, 2018 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of IND ready antibodies and bispecifics, cancer vaccines, and adoptive cell therapies1, today announced the appointment of I-O drug development experts into key leadership positions.  These appointments will help advance multiple clinical programs and planned BLA filings by 2020. Drs. Gupta and Wijatyk have had successful careers leading the approvals of immune therapies and chemotherapies," said Garo H. Armen, Ph.D., Chairman and CEO of Agenus. Dr. Sunil Gupta joins Agenus as Vice President of Regulatory and Pharmacovigilance.  Dr. Gupta is a trained oncologist with nearly 30 years in senior leadership positions in clinical development and regulatory affairs.


Agenus to Webcast Annual Meeting of Stockholders
Posted on Wednesday June 20, 2018

LEXINGTON, Mass. , June 20, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 invites ...


National Advisory Committee on Immunization (NACI) recommends SHINGRIX for the prevention of shingles for adults aged 50 and up
Posted on Monday June 18, 2018

National Advisory Committee on Immunization (NACI) recommends SHINGRIX for the prevention of shingles for adults aged 50 and up


Agenus Discovery Enhances Activity of Cancer Fighting Antibodies; Findings Published in Cancer Cell
Posted on Tuesday June 12, 2018

LEXINGTON, Mass., June 12, 2018 /PRNewswire/ -- A study published in Cancer Cell reports on a novel discovery made by Agenus Inc. (AGEN) that may enhance the immune activity of cancer fighting antibodies, including those targeting CTLA-4.  Agenus has applied this discovery to its proprietary next generation anti-CTLA-4 antibody (AGEN1181) on track for IND filing in 2H2018. The pre-clinical study reports on a unique mechanism discovered by Agenus, that can significantly improve the biological and immunological activity of certain cancer fighting antibodies, such as those targeting CTLA-4 and TIGIT.


Enter a stock symbol to view the stock details.